Eptifibatide is an antiplatelet drug that reversibly binds and inhibits glycoprotein IIb/IIIa receptor of platelets. A protein found in the venom of a southeastern pygmy rattlesnake is used to make eptifibatide. The PURSUIT and IMPACT-II account for the indications of eptifibatide by Food and Drug Administration(FDA)as mentioned below:
Non-FDA-labeled indications are:
Rupture of atherosclerotic plaque or injury to the vessel wall exposes the subendothelial matrix of the coronary blood vessel to circulating platelets. This event triggers a platelet signaling cascade that leads to the activation of the glycoprotein IIb/IIIa receptor (GpIIb/IIIa). The activation of Gp IIb/IIIa receptors leads to cross-linking of fibrinogen to attach multiple platelets to form a durable secondary platelet plug. The secondary platelet plug is essential for the progression and stability of the clot. The glycoprotein IIb/IIIa receptor inhibitors, including abciximab, eptifibatide, sibrafiban, and tirofiban, which block the activation of Gp IIb/IIIa receptors, ultimately preventing clot formation/progression.
GP IIb/IIIa heterodimer contains a large extracellular region, a transmembrane domain, and a short intracellular cytoplasmic tail. The Gp IIb/IIIa receptor is a calcium and manganese-dependent heterodimer protein consisting of an alpha- and a beta-subunit. The alpha-subunit characterized by three or four divalent Ca- or Mn-binding domains that are crucial in the GP IIb/IIIa heterodimer. The beta-subunit comprises of disulfide bonds, binding sites including lysine-glycine-aspartic acid (KGD) bindings binding sites, or arginine-glycine-aspartic acid (RGD) for attachment of fibrinogen, von Willebrand factor (vWF) and prothrombin. The binding sites of GP IIb/IIIa are hidden as latent and become active on the surface by undergoing a conformational change via inside-out signaling.
The eptifibatide is a natural disintegrin from snake venom and have highly specific binding to the Gp IIb/IIIa receptor because of the structural resemblance of KGD (Lys-Gly-Asp) sequence. Eptifibatide binds to the KGD binding sites on Gp IIb/IIIa receptor and competitively fights against the binding of the receptor with fibrinogen, von Willebrand factor (vWF) and prothrombin. Higher plasma levels of eptifibatide are needed to competitively inhibit the target of over 80% block of KGD binding sites. Eptifibatide can competitively inhibit the KGD (Lys-Gly-Asp) sequence binding site in both active and inactive states. Eptifibatide has a half-life of 2 to 2.5 hrs and cleared by the kidney. The low affinity for direct binding with GP IIb/IIIa is responsible for rapid states. Furthermore, high doses of eptifibatide provide additional antithrombotic benefits by blocking the vitronectin binding site, the ligand for alpha-beta in vascular cells, which may offer other antithrombotic benefits.
Eptifibatide is intravenously administered and is available in strengths of 0.75 mg/ml and 2 mg/ml. The dose of eptifibatide is different in patients diagnosed with acute coronary syndrome (ACS) and in patients undergoing percutaneous coronary intervention (PCI). In patients with ACS, it is given immediately after the diagnosis at a loading dose of 180 mcg/kg IV, followed by a continuous IV infusion of 2 mcg/kg/min. The infusion continues up to 72 hours. Pre-PCI, eptifibatide is given as a loading dose of 180 mcg/kg IV, followed by a continuous infusion of 2 mcg/kg/min with another 180 mcg/kg IV bolus (double bolus regimen) given 10 minutes after the first one. Status post-PCI eptifibatide infusion continued up to 18 hours. Kidney clears eptifibatide; a maintenance dose is cut down to 50% in patients with serum creatinine greater than 2 mg/dL and keeping loading dose the same as that of a normal kidney function. Contraindications to eptifibatide in patients with serum creatinine greater than 4 mg/dL or patients requiring hemodialysis.
In ACS, eptifibatide is a therapeutic option along with other medications, including alteplase, heparin, metoprolol, nitroglycerin, morphine, or furosemide. Eptifibatide is chemically incompatible with furosemide, and thus they should not be administered in the same intravenous line.
The significant side effect of eptifibatide described in the PURSUIT trial was bleeding. In most cases, bleeding was mild and occurred at femoral access sites. There were more red cell transfusions required in the eptifibatide group compared to placebo to counteract anemia. However, there is increased bleeding following abciximab administration compared to eptifibatide or tirofiban because of the rapid reversibility of these latter two agents.
Thrombocytopenia is another side effect of eptifibatide reported in several case reports. Thrombocytopenia infrequently occurs with Gp IIb/IIIa inhibitors but sometimes may be profound. The risk of thrombocytopenia associated with eptifibatide (0.1 to 0.2%) and tirofiban (0.1 to 0.3%) is lesser compared to abciximab (0.4 to 1.1%). Tirofiban induced thrombocytopenia (secondary to eptifibatide) occurs because of the naturally occurring drug-dependent antibodies specific for eptifibatide occupied Gp IIb/IIIa receptor site. It is also clinically relevant to distinguish eptifibatide-induced thrombocytopenia from other etiologies. Pseudothrombocytopenia is detectable using complete blood cell analysis when blood samples are collected in EDTA- containing tubes. The absence of platelet clumping on peripheral smear rules out pseudo-thrombocytopenia. Among the Gp IIb/IIIa inhibitors, only abciximab has reportedly shown an association with pseudo-thrombocytopenia. Heparin and eptifibatide are administered simultaneously during PCI and in the treatment of ACS. In comparison to heparin-induced thrombocytopenia (HIT), eptifibatide usually causes a steep decline in platelet count (less than 30000 cells/ uL). HIT-1 occurs within one and five days, whereas HIT-2 occurs within 4 to 20 days following heparin administration. Thus thrombocytopenia developing within the first day or severe thrombocytopenia favor thrombocytopenia secondary to eptifibatide. Also, the detection of platelet factor-4 (PF-4) assay in HIT can help differentiate it from eptifibatide-induced thrombocytopenia. Eptifibatide can inhibit new platelets in both active and inactive states. Thrombocytopenia due to eptifibatide responds better after discontinuation of medication, and the addition of a platelet bag is not helpful if the patient has a high concentration of eptifibatide in plasma. Other side effects reported include hypotension, heart failure, arrhythmias (ventricular fibrillation, atrial fibrillation), hypersensitivity reactions, gastrointestinal, genitourinary, or pulmonary alveolar hemorrhage.
The contraindications to using eptifibatide mentioned below:
Eptifibatide is a pregnancy category B drug. It should only be used cautiously in lactating mothers. Also, the drug is not recommended for use in the pediatric population.
Monitor complete blood count (CBC), serum creatinine, and PT/aPTT. In patients undergoing PCI, measure activated clotting time (ACT).
Bleeding at intravenous sites is the most common adverse effect. Simultaneous use of NSAIDs or other antiplatelet drugs and renal insufficiency would increase the risk of bleeding.
There is no specific antidote for eptifibatide toxicity. Clinicians should discontinue eptifibatide when platelet counts are under 50000 cells/microliter, and a platelet transfusion ordered when platelet counts are less than 20000 cells/microliter, or there is significant bleeding.
Eptifibatide is useful in the treatment of acute coronary syndrome (ACS) and following percutaneous coronary intervention (PCI). Healthcare workers, including nurses, pharmacists, and clinicians, should be aware that bleeding and thrombocytopenia are major complications following eptifibatide administration, and they should work together as a team to identify these complications. Nursing should be first in line for monitoring for adverse events, especially bleeding, and pharmacists should conduct thorough medication reconciliation and verify dosing since medication errors in either of these areas can lead either to therapeutic failure or severe bleeding. Any concerns in these areas require immediate communication with the physician in charge, as well as the rest of the team involved in care. Only through this type of interprofessional collaboration can patients achieve optimal therapeutic outcomes with eptifibatide. [Level 5]
Also, since heparin is used in conjunction with eptifibatide in the treatment of ACS and during PCI, it is imperative to learn how to differentiate heparin-induced thrombocytopenia from eptifibatide-induced thrombocytopenia.
|||Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The New England journal of medicine. 1998 Aug 13; [PubMed PMID: 9705684]|
|||Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet (London, England). 1997 May 17; [PubMed PMID: 9164315]|
|||Gibson CM,Kirtane AJ,Murphy SA,Rohrbeck S,Menon V,Lins J,Kazziha S,Rokos I,Shammas NW,Palabrica TM,Fish P,McCabe CH,Braunwald E, Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. American heart journal. 2006 Oct [PubMed PMID: 16996831]|
|||Ohman EM,Kleiman NS,Gacioch G,Worley SJ,Navetta FI,Talley JD,Anderson HV,Ellis SG,Cohen MD,Spriggs D,Miller M,Kereiakes D,Yakubov S,Kitt MM,Sigmon KN,Califf RM,Krucoff MW,Topol EJ, Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation. 1997 Feb 18 [PubMed PMID: 9054741]|
|||Adeoye O,Sucharew H,Khoury J,Vagal A,Schmit PA,Ewing I,Levine SR,Demel S,Eckerle B,Katz B,Kleindorfer D,Stettler B,Woo D,Khatri P,Broderick JP,Pancioli AM, Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial. Stroke. 2015 Sep [PubMed PMID: 26243231]|
|||Sangkuhl K,Shuldiner AR,Klein TE,Altman RB, Platelet aggregation pathway. Pharmacogenetics and genomics. 2011 Aug; [PubMed PMID: 20938371]|
|||Schrör K,Weber AA, Comparative pharmacology of GP IIb/IIIa antagonists. Journal of thrombosis and thrombolysis. 2003 Apr [PubMed PMID: 14618072]|
|||Coller BS, Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation. 1995 Nov 1 [PubMed PMID: 7586333]|
|||Chong PH, Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 1998 Nov 15 [PubMed PMID: 9825033]|
|||Madan M,Berkowitz SD,Tcheng JE, Glycoprotein IIb/IIIa integrin blockade. Circulation. 1998 Dec 8 [PubMed PMID: 9843473]|
|||Leclerc JR, Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions. Critical care medicine. 2002 May [PubMed PMID: 12004256]|
|||O'Shea JC,Hafley GE,Greenberg S,Hasselblad V,Lorenz TJ,Kitt MM,Strony J,Tcheng JE, Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA. 2001 May 16; [PubMed PMID: 11368699]|
|||Oak MS,Rege NN, Eptifibatide: in the treatment of acute coronary syndromes. Journal of postgraduate medicine. 2000 Apr-Jun; [PubMed PMID: 11013490]|
|||Lefkovits J,Plow EF,Topol EJ, Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. The New England journal of medicine. 1995 Jun 8; [PubMed PMID: 7739710]|
|||Hongo RH,Brent BN, Association of eptifibatide and acute profound thrombocytopenia. The American journal of cardiology. 2001 Aug 15; [PubMed PMID: 11545770]|
|||Tempelhof MW,Benzuly KH,Fintel D,Krichavsky MZ, Eptifibatide-induced thrombocytopenia: with thrombosis and disseminated intravascular coagulation immediately after left main coronary artery percutaneous coronary angioplasty. Texas Heart Institute journal. 2012; [PubMed PMID: 22412237]|
|||Sane DC,Damaraju LV,Topol EJ,Cabot CF,Mascelli MA,Harrington RA,Simoons ML,Califf RM, Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. Journal of the American College of Cardiology. 2000 Jul; [PubMed PMID: 10898416]|
|||Dager WE,Dougherty JA,Nguyen PH,Militello MA,Smythe MA, Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy. 2007 Apr; [PubMed PMID: 17381384]|
|||Schneider DJ, Anti-platelet therapy: glycoprotein IIb-IIIa antagonists. British journal of clinical pharmacology. 2011 Oct [PubMed PMID: 21906121]|